Trypto Therapeutics GmbH

TRYPTO THERAPEUTICS is developing a set of novel, proprietary small molecules at TRL level 4 to treat serotonin-related diseases.

We have developed and patented a novel class of TPH inhibitors (TPHi) with nanomolar potency in vitro.

Our TPHi differ in their scaffold, binding mode, and potency from TPHi that are currently on the market or under clinical investigation.

The lead TPHi compound achieved readiness to transition from academic research towards a targeted pharmaceutical development.